Galangin

Galangin: A Comprehensive Reference

1. Identity, Chemistry, and Natural Sources

Chemical Identity

Galangin is a flavonol, a type of flavonoid. Its systematic chemical name is 3,5,7-trihydroxyflavone — a kind of flavonoid with a hydroxyl substitution at positions 3, 5, and 7 of the flavone skeleton. Its CAS number is 548-83-4, and it carries the synonyms NSC 407229 and 3,5,7-Trihydroxyflavone. The full IUPAC-style name used in pharmacological literature is 3,5,7-trihydroxy-2-phenylchromen-4-one (3,5,7-trihydroxyflavone).

The chemical moiety present in galangin is 4H-1-benzopyran-4-one, 3,5,7-trihydroxy-2-phenyl, which can be synthesized by refluxing 2-methoxy-1-(2,4,6-trihydroxyphenyl)ethanone with benzoic acid and benzoyl chloride. Galangin is a flavonol derivative that does not have any hydroxyl group in the B-ring, but has a 2,3-double bond with a 3-hydroxyl group in the C-ring and 5,7-dihydroxyl groups in the A-ring. Galangin is the most lipophilic compound among similar flavonol compounds such as quercetin, kaempferol, morin, and myricetin.

Due to its structure, particularly the presence of hydroxyl groups, galangin (3,5,7-trihydroxyflavone) effectively functions as an antioxidant. This functionality arises from its ability to readily donate a hydrogen atom, specifically from its 3-hydroxyl group, transforming a portion of the molecule into a 3-flavonoid phenoxyl radical.

Galangin suffers from disadvantages of poor solubility in water and low stability to oxidation. Researchers have explored cyclodextrin complexes to address this; studies examined complexes of flavonols such as galangin, kaempferol, and quercetin with cyclodextrins in order to improve their solubility.

Principal Botanical Sources

Galangin is found in high concentrations in plants like Alpinia officinarum (lesser galangal) and Helichrysum aureonitens. It is also found in the rhizome of Alpinia galanga and in propolis.

• Alpinia officinarum Hance (Lesser Galangal): Alpinia officinarum contains high concentrations of the flavonol galangin. Alpinia officinarum Hance (Zingiberaceae) has been used as a traditional Chinese medicine and food additive for centuries in China. Galangin is an indicator compound extracted from the root of this species, which also exists in Alnus pendula Matsum., Plantago major L., and Scutellaria galericulata L.
• Alpinia galanga (Greater Galangal): Alpinia galanga, a plant in the ginger family, bears a rhizome used largely as an herb in Unani medicine and as a spice in Southeast Asian cookery. It is one of four plants known as "galangal." Its common names include greater galangal, lengkuas, and blue ginger. The lesser galangal (A. officinarum) is the richer source of galangin as an isolated compound, while greater galangal's chemical profile differs significantly, being richer in 1′-acetoxychavicol acetate rather than galangin and diarylheptanoids.
• Propolis (Honeybee Resin): Alongside pinocembrin and chrysin, galangin ranks among the most abundant flavonoids discovered in honey. Studies on propolis have found that pinocembrin, pinobanksin, quercetin, chrysin, and galangin flavonoids and caffeic acid and coumaric acid phenolic acids are the most common components in propolis. Quantitative analyses from Turkish propolis samples found galangin at concentrations ranging from a minimum of 0.72 to a maximum of 40.79 mg/g. In European propolis, one study reported galangin content of 12.65–35.08 mg/g as relatively higher than other measured flavonoids such as quercetin, chrysin, hesperetin, kaempferol, and naringenin. Literature data showed that Populus nigra buds contained a variety of flavonoids including pinocembrin, pinobanksin, chrysin, galangin, vanillin, apigenin, and pinostrobin, which were also detected in propolis extracts, indicating that poplar bud resin is a key botanical source from which honeybees incorporate galangin into propolis.

2. Traditional and Historical Use

Traditional Chinese Medicine (TCM)

The dried root and rhizome of Alpinia officinarum Hance have been widely used in traditional Chinese medicine for thousands of years to alleviate pain, promote digestion, warm the stomach, and disperse cold. Known in TCM as Gao Liang Jiang (高良姜) or Lesser Galangal Rhizome, its rhizome — the underground stem — is dried and used for its spicy, warming properties. Its use dates back to at least the Eastern Han Dynasty, documented in texts such as the Mingyi Bielu as a "middle-grade" herb.

In TCM clinical practice, A. officinarum was used to warm the spleen and stomach, such as in Er Jiang Pill, which nourishes the spleen and stomach, removes cold, and eliminates phlegm. Additional classical prescriptions include Wenzhong Liangjiang Pill and Qing Zao San. A. officinarum is described in TCM as a pungent and hot substance that enters the spleen and stomach meridians, where it warms the stomach, reduces reflux, stops vomiting, and strengthens the spleen and stops diarrhea — for example, Ding Qi San was used for vomiting induced by typhoid.

Ayurveda and Unani

Both Alpinia officinarum and Alpinia galanga are recognized across Indian medicinal traditions. Alpinia galanga bears a rhizome used largely as an herb in Unani medicine and as a spice in Southeast Asian cookery. The name "galangal" is probably derived from Persian qulanjan or Arabic khalanjan, which in turn may be an adaptation of Chinese gao liang jiang. Its names in North India are derived from the same root, including kulanja in Sanskrit, kulanjan in Hindi, and kholinjan in Urdu. In Ayurvedic practice, Alpinia officinarum was typically administered as a powdered rhizome (churna), decoction (kwatha), or medicated oil for external use.

Southeast Asia and the Spice Trade

Greater galangal (A. galanga), also known as greater galangal or Kulingen, has been used for thousands of years in Southeast Asia as a spice, while it is also of great importance in traditional medicine for the treatment of various diseases including microbial infections, rheumatic pains, dyspepsia, diabetes, eczema, ulcers, and other dermatological disorders. Its original center of cultivation during the spice trade was Java, and today it is still cultivated extensively in Island Southeast Asia, most notably in the Greater Sunda Islands and the Philippines. Cultivation has also spread into Mainland Southeast Asia, most notably Thailand.

Medieval Europe

The galangal rhizomes were widely used in ancient and medieval Europe, where they were reputed to smell of roses and taste of sweet spice. Their use in Europe has dramatically declined. In medieval Europe, galangal was celebrated in herbal texts by Hildegard of Bingen and others as a tonic for vitality. Historically, the rhizomes were reputed to have stimulant and digestive effects.

3. Key Constituents and Phytochemical Context

Galangin is one of multiple bioactive compounds present in Alpinia species. Other co-occurring constituents of note in these plants include cineol, eugenol, sesquiterpenes, resin, kaempferol, galangin, starch, flavonoids, phenolic acids, methyl cinnamate, and terpenes. In Alpinia galanga specifically, major phenylpropanoid constituents include 1′S-1′-acetoxychavicol acetate (ACA) and 1′S-1′-acetoxyeugenol acetate (AEA), which have been reported to possess various biological activities.

Galangin itself — as the principal isolated flavonol of A. officinarum — is the focus of the majority of pharmacological research. Galangin has three hydroxyl groups on its carbon rings, acts as an enzyme modulator, and can reduce chemical genotoxicity. Studies have proven that galangin is converted in the liver to kaempferol and quercetin by cytochrome P450, both of which have antioxidant properties.

4. Pharmacokinetics

Absorption, Distribution, and Elimination

Using ultra-high-performance liquid chromatography–tandem mass spectrometry (UHPLC–MS/MS), researchers studied the pharmacokinetic properties of galangin and discovered that when it was administered orally or via intraperitoneal injection to a rat model, it was quickly absorbed (tmax = 0.25 h) and eliminated (t1/2 < 1.1 h) with an absolute bioavailability of 7.6%. Galangin was found in high amounts in the kidney, liver, and spleen, and was also able to cross the blood–brain barrier to reach the brain, although in lower concentrations.

Metabolism

Galangin undergoes metabolism through glucuronidation reaction, producing metabolites such as galangin-3-O-β-D-glucuronic acid (GG-1) and galangin-7-O-β-D-glucuronic acid (GG-2). It is well reported that galangin gets oxidized to kaempferol; however, it is metabolized preferentially by glucuronide conjugation rather than sulfation and oxidation reactions. An assay using recombinant human CYP1A1 revealed that CYP1A1 oxidized galangin to kaempferol in Caco-2 intestinal cells.

Some studies have confirmed that glucuronidated metabolites of galangin have better bioactivities than the parent galangin, suggesting a need to evaluate these active metabolites as potentially more effective, safer drug candidates.

A study employed high-performance liquid chromatography (HPLC) to track galangin levels in rats after intraperitoneal injection, revealing an initial drop in blood levels at 5 minutes and a peak level at 8 hours, indicating potential circulation within the liver and intestines.

5. Mechanisms of Action

Antioxidant Mechanisms

Galangin has garnered attention for its robust antioxidant and anti-inflammatory properties. Research indicates that it demonstrates protective effects against cellular damage induced by oxidative stress by modulating intracellular communication and boosting the activity of endogenous antioxidant enzymes. In animal studies, galangin increased the expression of peroxisome proliferator-activated receptor gamma (PPARγ) and activated hepatic nuclear factor erythroid 2-related factor 2 (Nrf2) signaling, as shown by increases in Nrf2, NAD(P)H:quinone acceptor oxidoreductase-1 (NQO-1), and heme oxygenase-1 (HO-1).

Anti-Inflammatory Mechanisms

Galangin's multifaceted anti-inflammatory actions include NF-κB inhibition, cytokine reduction, matrix metalloproteinase (MMP) control, and Nrf2 activation. Its mechanisms of action focus on interactions with key inflammatory cytokines (e.g., TNF-α, IL-6), enzymes (e.g., SOD, MMPs), and signaling pathways (e.g., NF-κB, MAPK), which impact inflammatory responses, immune cell activation, and joint damage.

In cell studies, galangin treatment efficiently protected renal epithelial cells against uric-acid-induced inflammation by decreasing tumor necrosis factor (TNF)-α, interleukin (IL)-1β, IL-18, prostaglandin E2 (PGE2), and nitric oxide (NO) release, and it inhibited related mRNA expression. Western blotting showed that galangin treatment effectively inhibited nuclear factor-kappa B (NF-κB), phosphatidylinositol 3 kinase (PI3K)/protein kinase B (AKT), and nucleotide-binding domain-like receptor protein 3 (NLRP3) signaling pathway activation.

Anticancer Mechanisms

Galangin modulates immunity and oxidative stress and induces apoptosis in cancer cells. Key pathways modulated include PI3K/Akt, MAPK, AMPK, and NF-κB, targeting a variety of cancer types. Anti-angiogenic and anti-metastatic actions include inhibiting p-Akt, p-70S6K, HIF-1, VEGF/R and Erk1/2, c-Fos, c-Jun, NF-κB, and AP-1 pathways.

In cholangiocarcinoma (CCA) cells, galangin treatment was found to upregulate the expression of PTEN and downregulate the phosphorylation of AKT via miR-21 inhibition. Using hepatocellular carcinoma (MHCC97H) cells, galangin was found to inhibit the expression of H19 and miR-675 via upregulating p53 levels.

Airway Epithelial Effects

Studies investigating the effects of galangin on the expression of the mucin 5AC (MUC5AC) gene in airway cells found that human pulmonary epithelial NCI-H292 cells pretreated with galangin and then stimulated with phorbol 12-myristate 13-acetate (PMA) showed inhibition of glycoprotein production and MUC5AC mRNA expression, via prevention of NF-κB inhibitor α degradation and NF-κB p65 nuclear translocation.

Enzyme Modulation and the Aryl Hydrocarbon Receptor

Galangin has been shown to be a strong inhibitor of the aryl hydrocarbon receptor in earlier studies. Galangin inhibited the catabolic breakdown of the carcinogen DMBA in a dose-dependent manner; also inhibited the formation of DMBA-DNA adducts, and prevented DMBA-induced inhibition of cell growth. It caused a potent, dose-dependent inhibition of CYP1A1 activity, as measured by ethoxyresorufin-O-deethylase activity, in intact cells and in microsomes.

6. Scientific Evidence by Health Area

6.1 Cancer (In Vitro and Animal Studies)

Evidence level: Preclinical only (in vitro and animal models). No human clinical trials confirmed to date.

The multifaceted anti-cancer action of propolis-derived flavonoid galangin encompasses its antioxidant, anti-inflammatory, antiproliferative, pro-apoptotic, anti-angiogenic, and anti-metastatic effects in various cancer cells. Although clinical studies on the anticancer effects of galangal or its active components are currently lacking, the preclinical literature is extensive.

Regarding hepatocellular carcinoma, 50 lncRNAs were found significantly differentially expressed in MHCC97H cells treated with galangin. The expression of H19 was markedly reduced following treatment with galangin in MHCC97H cells, and the galangin-treated group showed inhibited cell migration.

In breast cancer models, galangin was shown to induce apoptosis in MCF-7 human breast cancer cells through the mitochondrial pathway and phosphatidylinositol 3-Kinase/Akt inhibition. In liver cancer cell lines (HepG2), galangin was shown to attenuate metastatic features via the PKC/ERK signaling pathway in TPA-treated liver cancer HepG2 cells.

Galangin's co-effects with standard chemotherapeutic drugs as well as other natural compounds are under discussion, besides modern nanotechnological advancements for overcoming galangin's low bioavailability. There is much more need for extensive studies to prove the efficacy of galangin as an anticancer agent in human volunteers and to ensure its safety and efficacy in the human system.

6.2 Inflammation and Rheumatoid Arthritis (Preclinical)

Evidence level: Preclinical (in vitro and animal models). No registered human clinical trials identified.

Studies suggest that galangin, a natural flavonoid compound found in various plants such as Alpinia officinarum and Alpinia galanga, holds potential as a therapeutic agent for treating rheumatoid arthritis (RA). However, the need for further research and clinical studies to ascertain the effectiveness of galangin in RA treatment and to elucidate its mechanisms of action has been underscored by reviewers.

6.3 Hepatoprotection (Animal Studies)

Evidence level: Animal studies only.

A study investigated the hepatoprotective effect of galangin in cyclophosphamide (CP)-induced rats. Rats received galangin at 15, 30, and 60 mg/kg/day for 15 days, followed by a single dose of CP at day 16. CP triggered liver injury characterized by elevated serum transaminases, alkaline phosphatase (ALP), and lactate dehydrogenase (LDH), and histopathological manifestations. Galangin prevented CP-induced liver injury, boosted antioxidants, and suppressed oxidative stress, DNA damage, NF-κB phosphorylation, and pro-inflammatory mediators. Galangin also diminished Bax and caspase-3 expression, and increased B-cell lymphoma-2 (Bcl-2) in the liver of CP-administered rats. These findings suggest that galangin prevents CP hepatotoxicity through activation of Nrf2/HO-1 signaling and attenuation of oxidative damage, inflammation, and cell death, and it might represent a promising adjuvant therapy.

Galangin was also reported to protect against carbon tetrachloride (CCl4)-induced hepatotoxicity and fibrosis by mitigating oxidative stress and inhibiting hepatic stellate cell activation and proliferation. It was also found to reduce apoptosis by restoration of antioxidant defense mechanisms in ischemia-reperfusion-induced liver injury in rats.

6.4 Glycemic Control and Metabolic Effects (Animal Studies)

Evidence level: Animal studies only. One limited clinical observation exists for a galangal extract (not galangin isolate).

Galangin from the rhizome of Alpinia galanga given orally at a dose of 100 mg/kg/day for 16 days to fructose-fed Wistar rats lowered glucose from 120.6 to 73.8 mg/dL (normal: 69.8 mg/dL), triglycerides from 163.4 to 98.5 mg/dL (normal: 91.6 mg/dL), decreased plasma insulin from 62.6 to 33.5 μU/mL (normal: 34.2 μU/mL), and increased insulin sensitivity by improving glucose clearance by skeletal muscles and/or adipocytes. At a concentration of 30 μM, this flavone induced glucose uptake by L6 myotubes in vitro as efficiently as insulin at 0.1 μM.

According to a clinical study, giving men with idiopathic infertility 300 mg of Alpinia officinarum Hance rhizome extract orally every day may increase the quantity and quality of sperm. This observation involved the whole plant extract rather than isolated galangin, and should be interpreted accordingly.

6.5 Neuroprotection (Animal Studies)

Evidence level: Animal studies only. Clinical trials are required.

A study evaluated the neuroprotective effects and underlying mechanisms of galangin in mitigating oxidative stress, inflammation, and apoptosis in a rat model of permanent cerebral ischemia, using sixty male Wistar rats divided into six groups including a control, a middle cerebral artery occlusion (MCAO) with vehicle group, a piracetam-treated group, and galangin groups administered at doses of 25, 50, and 100 mg/kg body weight. Results demonstrated that galangin treatment significantly improved neurological deficit scores, reduced brain edema, enhanced neuronal density, attenuated microglial activation, decreased MPO activity, and increased SOD activity in both the cortex and hippocampus. These effects were linked to the modulation of inflammatory and apoptotic pathways; specifically, galangin significantly reduced the expression of IL-6, COX-2, Bax, and caspase-3 while increasing the levels of the anti-apoptotic protein Bcl-XL. In conclusion, galangin demonstrates significant promise as a neuroprotective agent for ischemic stroke by suppressing inflammation and apoptosis, thereby improving neurological outcomes; however, clinical trials are required to validate these preclinical findings.

6.6 Cardiovascular Effects (Animal Studies)

Evidence level: Animal studies only.

To investigate the effect of galangin on blood pressure and vascular changes, male Wistar rats (220–250 g) were given L-NAME (0.5 mg/mL in drinking water) to induce hypertension for 5 weeks, and were then treated with vehicle, galangin (30 or 60 mg/kg), or amlodipine (10 mg/kg) for the final two weeks (n = 6/group). Galangin significantly reduced blood pressure and improved impairment of endothelium-dependent vasodilation in hypertensive rats.

6.7 Atopic Dermatitis and Skin Conditions (Animal and Cell Studies)

Evidence level: Animal models and in vitro cell studies only.

Researchers investigated the effects of galangin on atopic dermatitis (AD)-like skin lesions by establishing an atopic dermatitis model in BALB/c mice using repeated local exposure to house dust mite extract and 2,4-dinitrochlorobenzene to the ears. Topical application of galangin reduced AD symptoms based on ear thickness and histopathological analysis, in addition to serum IgE and IgG2a levels. Galangin inhibited mast cell infiltration into the ear and serum histamine level, and suppressed DFE/DNCB-induced expression of interleukin (IL)-4, IL-5, IL-13, IL-31, IL-32, and interferon (IFN)-γ in the ear tissue. Galangin significantly inhibited the expression of cytokines and chemokines by the down-regulation of NF-κB and mitogen-activated protein kinases in HaCaT keratinocyte cells, and the results demonstrate that galangin inhibited AD-like symptoms, suggesting it might be a candidate for the treatment of AD. Another study showed that galangin can protect human keratinocytes against ultraviolet B-induced oxidative damage.

6.8 Respiratory / Airway Effects (Preclinical)

Evidence level: Animal and cell models only.

Research found that galangin can inhibit airway inflammation and airway hyperresponsiveness to some extent in a mouse model of asthma. In airway epithelial cells, galangin inhibited the production of glycoproteins and the expression of MUC5AC mRNA induced by PMA via prevention of NF-κB inhibitor α degradation and NF-κB p65 nuclear translocation, pointing to potential utility in conditions characterized by excessive mucin production.

6.9 Antimicrobial and Antiviral Activity (In Vitro)

Evidence level: In vitro only.

Galangin has been shown to have in vitro antibacterial and antiviral activity. Galangin has been reported to have anti-microbial and anti-viral effects. In propolis research, the antibacterial effectiveness of galangin and related polyphenols was modeled using in silico analyses, suggesting promiscuous binding of all tested polyphenolic ligands to target enzymes. All antimicrobial and antiviral findings for galangin as an isolated compound remain in the in vitro stage.

7. Body Systems Associated with Galangin Research

• Immune and inflammatory system: Galangin's bioactive properties include anti-inflammatory, antioxidant, and immunomodulatory effects.
• Oncology: Increasing attention has been paid to the role of galangin in cancer research.
• Hepatic system: Preclinical investigations have demonstrated the antioxidant and anti-inflammatory efficacies of galangin in animal models of hepatotoxicity and other liver conditions.
• Cardiovascular system: Biological activities of galangin include antihypertensive effects studied in preclinical models.
• Metabolic/endocrine system: Galangin has been reported to show antidiabetic activity.
• Nervous system: Galangin exhibits promise in diverse therapeutic applications spanning from neuroprotection to cognitive support, based on animal studies.
• Musculoskeletal system: Galangin has attracted attention in rheumatoid arthritis, osteoarthritis, and osteoporosis research.
• Skin/integumentary system: Galangin has been studied in the context of skin diseases including atopic dermatitis and UV-induced damage.
• Respiratory system: Preclinical studies support investigation into airway inflammatory conditions including asthma and mucus hypersecretion.

8. Dosage Forms and Doses Reported in Studies

No standardized human dosing recommendations for isolated galangin are established by any pharmacopeia or government health body, as clinical trials in humans are essentially absent. The following doses are those reported in preclinical animal studies:

• In a hepatoprotection study, rats received galangin at 15, 30, and 60 mg/kg/day for 15 days followed by a single dose of cyclophosphamide at day 16.
• In a hypertension model, rats were given galangin at 30 or 60 mg/kg for two weeks.
• In the ischemic stroke model, galangin was administered to rats at doses of 25, 50, and 100 mg/kg body weight.
• In a metabolic/fructose-fed rat study, galangin was given orally at 100 mg/kg/day for 16 days.
• In the CYP450 interaction study, male Sprague Dawley rats were administered galangin daily for 8 weeks.
• One clinical observation involved the whole plant: 300 mg of Alpinia officinarum Hance rhizome extract orally every day was given to men with idiopathic infertility. This dose relates to the plant extract rather than isolated galangin.

Regarding formulation research, PEG-modified liposomes have demonstrated enhanced solubility, antitumor effectiveness, and pharmacokinetics when compared to free galangin. Cyclodextrin-inclusion complexes are another investigated approach to improve galangin's water solubility and bioavailability.

9. Safety Considerations and Drug Interactions

Acute Toxicity

Based on reported data, orally administered galangin displayed no signs of toxicity in male Wistar rats at doses up to 320 mg/kg. In addition, no significant histological changes were observed in the liver, renal, heart, and lung tissues of male nude mice following intraperitoneal injection. In a mouse model using galangin/β-cyclodextrin complex, the inclusion complex did not have a significant influence on normal cells as indicated by serum levels of kidney and liver enzymatic markers, as well as thymic and splenic mass indices, and no pathological alterations were observed in the liver, kidney, thymus, spleen, heart, or lung upon histological analysis.

Cytochrome P450 Interactions

Galangin is a marker compound of honey and Alpinia officinarum that is frequently consumed in combination with common clinical drugs. Studies have evaluated the effects of galangin on cytochrome P450 (CYP)-mediated metabolism to predict drug–drug interactions. The galangin-treated group showed significantly decreased AUC and Cmax values for CYP1A2 and CYP2B3, and significantly increased AUC and Cmax values for CYP2C13 and CYP3A1. No significant influences were observed in the pharmacokinetic profiles of CYP2C11, CYP2D4, and CYP2E1. Thus, CYP450 enzyme activities may be altered by long-term galangin administration. When taking medications that are substrates of affected CYP enzymes, simultaneous intake of Chinese herbal medicine or dietary supplements containing galangin or related ingredients may lead to fluctuations of the therapeutic effect or increases in metabolite concentrations and subsequent adverse reactions. These interactions have only been studied in rats.

Genotoxicity

Galangin has three hydroxyl groups on its carbon rings, acts as an enzyme modulator, and can reduce chemical genotoxicity. Since phenolics may exert a dual nature — both pro-oxidant and antioxidant — the safety profile of the ethanolic extract of propolis and the related flavonoid galangin, and their ability to protect lymphocytes from irinotecan-induced cyto/genotoxicity, have been investigated in vitro. Historically, some flavonoid aglycones showed mutagenicity in bacterial test systems (Salmonella typhimurium); flavonoids are generally described as non-toxic and show a variety of beneficial biological activities, and are considered as possible chemopreventive agents against various diseases. No formal regulatory classification of galangin for genotoxicity has been identified in the searched literature.

Bioavailability Limitations

The absolute bioavailability of galangin following oral administration to rat models is 7.6%, which represents a significant pharmacokinetic challenge for its development as a therapeutic agent. Most natural products cannot be directly used as a drug due to their low biological availability, low bioactivity, and high toxicity and so on. Multiple nanotechnological strategies including liposomes, selenium nanoparticles, and cyclodextrin inclusion complexes are under active investigation to address these limitations.

Overall Evidence Limitations

There remains a need for extensive studies to be performed to prove the efficacy of galangin as anticancer, anti-inflammatory, and antioxidant agent in human volunteers and to ensure its safety and efficacy in the human system. The overwhelming majority of published research remains at the in vitro and rodent model level, and no large-scale randomized controlled trials in humans have been identified for any indication.

References

• Galangin: A Promising Flavonoid for the Treatment of Rheumatoid Arthritis—Mechanisms, Evidence, and Therapeutic Potential. PMC/NIH, 2024.
• Galangin: A food-derived flavonoid with therapeutic potential against a wide spectrum of diseases. Phytotherapy Research, 2023.
• Galangin alleviates vascular dysfunction and remodelling through modulation of the TNF-R1, p-NF-κB and VCAM-1 pathways in hypertensive rats. Life Sciences, 2021.
• Galangin. Wikipedia.
• Pharmacological activities and therapeutic potential of galangin, a promising natural flavone, in age-related diseases. Phytomedicine, 2023.
• Galangin: A metabolite that suppresses anti-neoplastic activities through modulation of oncogenic targets. PMC/NIH, 2022.
• Galangin Activates Nrf2 Signaling and Attenuates Oxidative Damage, Inflammation, and Apoptosis in a Rat Model of Cyclophosphamide-Induced Hepatotoxicity. PMC/NIH, 2019.
• Galangin Suppresses Renal Inflammation via the Inhibition of NF-κB, PI3K/AKT and NLRP3 in Uric Acid Treated NRK-52E Tubular Epithelial Cells. PMC/NIH, 2019.
• Galangin, a dietary flavonoid, ameliorates hyperglycaemia and lipid abnormalities in rats with streptozotocin-induced hyperglycaemia. PMC/NIH, 2018.
• Simultaneous determination of two galangin metabolites from Alpinia Officinarum Hance in rat plasma by UFLC-MS/MS and its application in pharmacokinetics study. PMC/NIH, 2021.
• Two Approaches for Evaluating the Effects of Galangin on the Activities and mRNA Expression of Seven CYP450. PMC/NIH, 2019.
• Stability Study of Alpinia galanga Constituents and Investigation of Their Membrane Permeability by ChemGPS-NP and the Parallel Artificial Membrane Permeability Assay. PMC/NIH, 2022.
• Galangin/β-Cyclodextrin Inclusion Complex as a Drug-Delivery System for Improved Solubility and Biocompatibility in Breast Cancer Treatment. PMC/NIH, 2022.
• Galangin Regulates Mucin 5AC Gene Expression via the NF-κB Inhibitor α/NF-κB p65 Pathway in Human Airway Epithelial Cells. PMC/NIH, 2025.
• Galangin's Neuroprotective Role: Targeting Oxidative Stress, Inflammation, and Apoptosis in Ischemic Stroke in a Rat Model. PMC/NIH, 2025.
• Galangin promotes cell apoptosis through suppression of H19 expression in hepatocellular carcinoma cells. PMC/NIH, 2020.
• Inhibitory effect of galangin on atopic dermatitis-like skin lesions. PubMed, 2014.
• Insights into the anticancer effects of galangal and galangin: A comprehensive review. Phytomedicine, 2024.
• The flavonoid galangin is an inhibitor of CYP1A1 activity and an agonist/antagonist of the aryl hydrocarbon receptor. PMC/NIH, 2008.
• Determination of antioxidant activity and phenolic compounds for basic standardization of Turkish propolis. PMC/NIH, 2021.
• Biological Activity and Chemical Composition of Propolis from Various Regions of Poland. PMC/NIH, 2023.
• Preliminary Insights into the Cyto/Genoprotective Properties of Propolis and Its Constituent Galangin In Vitro. PMC/NIH, 2025.
• Galangin, a novel dietary flavonoid, attenuates metastatic feature via PKC/ERK signaling pathway in TPA-treated liver cancer HepG2 cells. PMC/NIH, 2015.
• Alpinia officinarum Hance: a comprehensive review of traditional uses, phytochemistry, pharmacokinetic and pharmacology. PMC/NIH, 2024.
• Galangin: Advances on Resources, Biosynthesis Pathway, Bioavailability, Bioactivity, and Pharmacology. Springer, 2023.
• Anti-genotoxicity of galangin as a cancer chemopreventive agent candidate. Chemico-Biological Interactions, 2001.
• Metabolites of Galangin by TCDD-Inducible Cytochrome P450 1A1 in Human Intestinal Epithelial Caco-2 Cells and Their Antagonistic Activity toward Aryl Hydrocarbon Receptor. Journal of Agricultural and Food Chemistry, 2010.
• Alpinia officinarum. Wikipedia.
• Alpinia galanga. Wikipedia.
• Unveiling the Antioxidative Potential of Galangin: Complete and Detailed Mechanistic Insights through Density Functional Theory Studies. Journal of Organic Chemistry, 2024.